OOIR: Observatory of International Research

Papers

(The TQCC of Immunotherapy is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Imaging of brain metastases treated with immune checkpoint inhibitors	122
Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study	38
Atezolizumab and Bevacizumab prior to liver transplantation in hepatic angiosarcoma mimicking hepatocellular carcinoma	32
Cost–Effectiveness Analysis of Serplulimab as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma	32
Real-World Outcomes with Immuno-Oncology Therapies in Advanced Melanoma: Final Results of the OPTIMIzE Registry Study	27
Identifying risk factors and biomarkers for severe CIP in lung cancer patients– a retrospective case series study	27
Simulating a virtual tumor board with large language models: a pilot study in NSCLC patients receiving immunotherapy	23
Disrupting neuro-immune feedback loops: novel targets to amplify cancer immunotherapy	20
Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer Without Tumor Pd-L1 Expression in Asia	19
Postvaccination immune-mediated hepatitis: what do we really know?	19
MicroRNA prognostic markers for immune checkpoint inhibitor success in urologic cancers	18
Targeting PD-1/PD-L1 in Biliary Tract Cancer: Role and Available Data	18
Pembrolizumab in patients from China with microsatellite instability-high/mismatch repair deficient tumors: KEYNOTE-158	18
Pd-1, Pd-L1, Ido, Cd70 and Microsatellite Instability as Potential Targets to Prevent Immune Evasion in Sarcomas	18
Diagnostic and therapeutic evaluation of Blomia tropicalis in patients with allergic rhinitis	17
The role of bronchoscopic cryoimmunotherapy in non-small cell lung cancer: current evidence and future perspectives	16
Therapeutic lymph node dissection with neoadjuvant immunotherapy for macroscopic melanoma – too much skin in the game?	16
What is the future of immune checkpoints inhibitors for metastatic triple negative breast cancers?	15
Nivolumab induced discolouration of the tongue: a case report	15
Real-world data of immune-related adverse events in lung cancer patients receiving immune-checkpoint inhibitors	15
Anlotinib Succeeded in Rescue Therapy For Hyperprogression Induced by Immune Checkpoint Inhibitors: A Case Report	15
Cancer Immunotherapy Via Stem Cell-Derived NK Cells	15
Efficacy and safety of tarlatamab, a DLL3-targeted bispecific T-cell engager, in a patient with advanced esophageal small-cell neuroendocrine carcinoma: a case report	15
Adherence, persistence and treatment switching in psoriasis	14
Low-Dose Metronomic Gemcitabine Pretreatments Overcome the Resistance of Breast Cancer to Immune Checkpoint Therapy	13

A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors	13
Durvalumab after Chemoradiotherapy in Patients with Stage III Non-Small-Cell Lung Cancer: Real-World Outcomes Versus Clinical Trial Results	13
Sintilimab-induced severe erosive hemorrhagic gastritis and pyloric obstruction: a case report and literature review	12
Germinal center immune dynamics: challenges for effective vaccination in the elderly	12
Molecular Interactions of Antibodies with PD-1/PD-L1 Proteins	12
Lessons From the Diagnosis and Treatment of Severe Immune Checkpoint Inhibitor-Associated Pneumonia: A Case Report	12
Effectiveness of allergen immunotherapy with house dust mite extract for pediatric bronchial asthma	12
Gastrointestinal toxicities associated with immune checkpoint inhibitors therapy: risks and management	11
Dendritic Cell-Based Immunotherapy: A Potential Player in Oral Cancer Therapeutics	11
Durvalumab in Advanced Cholangiocarcinoma: Is Someone Knocking Down the Door?	11
Deucravacitinib in Moderate-To-Severe Psoriasis	11
Immune Checkpoint Inhibitors in Cholangiocarcinoma	11
Liquid biopsy for guiding breast cancer immunotherapy	11
Immunotherapy expectations and knowledge in practice and clinical trials: a cross-sectional study	11
SAFFRON-103: A Phase Ib Study of Sitravatinib Plus Tislelizumab in Anti-PD-(L)1 Refractory/Resistant Advanced Melanoma	10
Human Growth Hormone Supplement Promotes Human Lymphohematopoietic Cell Reconstitution in Immunodeficient Mice	10
Immune Checkpoint Inhibitor-Induced Autoimmune Encephalitis in Metastatic Squamous Cell Lung Cancer	10
Integrase inhibitors: current protagonists in antiretroviral therapy	10
Applications and Current Challenges of Chimeric Antigen Receptor T Cells in Treating High-Grade Gliomas in Adult and Pediatric Populations	10
Treatment of Plaque Psoriasis with Deucravacitinib (POETYK PSO-1 Study): A Plain Language Summary	10
Conversion surgery after pembrolizumab for initially unresectable MSI-H small bowel adenocarcinoma: a case report and brief analysis	10
Immune-Related Gigantomastia: A Case Study	10
Antithymocyte Globulin for Aplastic Anemia Secondary to Pembrolizumab: A Case Report and Review of Literature	10
Poor Response to Sintilimab Plus Chemotherapy in a Pulmonary Epithelioid Hemangioendothelioma Patient: A Case Report	10
Clinical optimization of bexmarilimab as a myeloid checkpoint therapy	10
Mepolizumab in Chronic Rhinosinusitis with Nasal Polyposis	9
Lebrikizumab decreases type 2 inflammatory biomarker levels in patients with asthma: data from randomized phase 3 trials (LAVOLTA I and II)	9
Ipilimumab and Nivolumab: The ‘New Kid on the Block’ in Advanced Angiosarcoma	9
Therapeutic Intervention of Glioma with the Novel Antineoplastic Agent T11TS: The Story so Far	9
Fulminant immune-related colitis after dual checkpoint inhibitor therapy: case report	9
Immune Checkpoint Inhibitors in Lung Tumors with Rare Histologies and Other Thoracic Malignancies	9
A Meta-Analysis of Application of Pd-1/Pd-L1 Inhibitor-Based Immunotherapy in Unresectable Locally Advanced Triple-Negative Breast Cancer	9
Cost-effectiveness of Upadacitinib vs. Tofacitinib for moderate-to-severe rheumatoid arthritis in China	9
Upadacitinib for the Treatment of Moderate-to-Severe Crohn’s Disease	9
Autophagy in combination therapy of temozolomide and IFN-γ in C6-induced glioblastoma: role of non-coding RNAs	9
TOPAZ-1: A New Standard of Care for Advanced Biliary Tract Cancers?	9
Steroid-Dependent Polyarthritis Induced by Immune Checkpoint Inhibitor Therapy Successfully Treated with Bimekizumab	9
Breaking the mold: nontraditional approaches to allergen immunotherapy for environmental allergens	9
Modified Dendritic cells as a therapeutic platform in hematologic malignancies with translational insights from central nervous system tumors	9
Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab	9
Optimizing TIL therapy for uveal melanoma: lessons learned and unlearned from cutaneous melanoma	9
Peripheral blood cytokines and outcomes with immune checkpoint blockade: a systematic review and meta-analysis	9
Infectious Adverse Events in Patients with Atopic Dermatitis Treated with Baricitinib	9
Impact of Helicobacter Pylori Infection on The Efficacy of Immune Checkpoint Inhibitors for Cancer Treatment: A Meta-Analysis	9
Abrocitinib for the Treatment of Atopic Dermatitis	9
Successful treatment of localized Merkel cell carcinoma with avelumab in a patient with amyotrophic lateral sclerosis	9
Pembrolizumab in an HIV-infected patient with glioblastoma	8
Amlitelimab, an anti-OX40 ligand antibody, for atopic dermatitis: a plain language summary of STREAM-AD clinical study	8
Validating Khorana Risk Score in gastric cancer patients on immune checkpoint inhibitors and chemotherapy	8
Intratumoral Delivery of Immune Therapy and Gene Therapy: The Next Era for Cancer Therapy	8

Simultaneous Inhibition of PD-1 and LAG-3: the Future of Immunotherapy?	8
Treatment patterns and outcomes in melanoma brain metastasis: exploring immune-related adverse events and survival	8
An Abscopal Effect in a Gastric Cancer Patient Treated with Combined Chemoimmunotherapy and Palliative Radiotherapy	8
Evaluating the Effectiveness of the Charlson Comorbidity Index in Predicting Immune Checkpoint Inhibitor-Related Adverse Events	8
Evaluating oral nutritional support and the nutritional risk scores in ICI-treated metastatic solid tumours	7
Established and Emerging Biomarkers of Immunotherapy in Renal Cell Carcinoma	7
Immune checkpoint inhibitors in POLE/POLD1 proofreading-deficient CRC: from molecular basis to clinical practice and future directions	7
Long-Term Response to Camrelizumab in a Pretreated Metastatic Mixed Testicular Germ-Cell Tumor Patient with Co-Mutations in DNA Damage-Repair Genes	7
Ocular Toxicities in Chimeric Antigen Receptor T-Cell Therapy: A Real-World Study Leveraging FAERS Database	7
Cutaneous Metastases at the Sites of Pembrolizumab-Induced Bullous Pemphigoid Lesions in a Patient with Melanoma	7
Combination of Methotrexate with Oral Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis: A Systematic Review	7
Evaluating Axatilimab as a treatment option for chronic graft-versus-host disease	7
Pathological Findings Directing Immunotherapy in Renal Cell Carcinomas	7
Immunotherapies for prevention and treatment of type 1 diabetes	7
Mirikizumab for the Treatment of Moderate to Severe Ulcerative Colitis	6
Gamma heavy chain disease treated with daratumumab-based regimen: a first case report and review of literature	6
Updated Insights on Cardiac Risks of CD19-Directed Chimeric Antigen Receptor T-cell Therapy: A Pharmacovigilance Study	6
Sarcoidosis-like reactions in metastatic renal cell carcinoma patients treated with immune-based combinations	6
Oncolytic Viruses in Lung Cancer Treatment: A Review Article	6
Neoadjuvant Immunochemotherapy in the Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: A Systematic Review	6
Sublingual immunotherapy suppresses Th2-type immune response in the allergic rhinitis mouse model by inhibiting the activation of the NFκB pathway	6
Fractional Exhaled Nitric Oxide in Checkpoint Inhibitor Pneumonitis: A Case Report and Literature Review	6
From blood draw to tumor infiltration: therapeutic variations in CAR-macrophage therapy for solid tumors	6
Next-generation cancer immunotherapy: the promise of CAR T-Cell therapy	6
Application of immune checkpoint inhibitors in immunotherapy for gastric cancer	6
Paraneoplastic dermatomyositis and Stevens-Johnson syndrome related to immunotherapy	6
Immunotherapy of endometrial cancer: a review of recent advances	6
Mitigation strategies for gastrointestinal (GI) immune-related adverse events for patients with solid tumors receiving immunotherapy	6
A New Perspective on The Potential Application of Ripk1 in the Treatment of Sepsis	6
Treatment of Plaque Psoriasis with Deucravacitinib (Poetyk Pso-2 Study): A Plain Language Summary	6
Moving Beyond Single-Agent Checkpoint Inhibition in Biliary Tract Cancers: What is the Next Frontier?	6
Allogeneic CAR-T cells for cancer immunotherapy	6
Could senescent cells be the prescription for therapeutic cancer vaccines?	6
The Development of Litifilimab (BIIB 059) for Cutaneous and Systemic Lupus Erythematosus	6
A novel dose-adjustment protocol for interrupted subcutaneous immunotherapy in children with allergic rhinitis	6
Immunotherapeutic effects of TCL-E5 and TCL-E5-pulsed DCs: two novel HPV therapeutic vaccine candidates	6
ICAM2 is Related to Good Prognosis in Dendritic Cell Immunotherapy for Cancer	6
Safety and Effectiveness of a 300 IR House Dust Mite Sublingual Tablet: Descriptive 4-Year Final Analysis of a Post-Marketing Surveillance in Japan	6
An Unusual Case of Immune-Related Gastritis in One Patient Receiving Toripalimab Therapy	6
Plain Language Summary of principles for improving the care of people with eosinophil-associated diseases	6
CAR cellular therapies for acute myeloid leukemia: current landscape and future directions	6
Effect of Helicobacter Pylori infection on immunotherapy for gastrointestinal cancer: a narrative review	5
The potential of phytomedicines to optimize CAR-T cell therapy in cancer	5
Amalgamation of Nanotechnology with Chicken IgY to Enrich Therapeutic and Diagnostic Applications: A Systematic Review	5
Efficacy of Long-Term Repeated Rituximab Treatment in Refractory Phospholipase A2 Receptor-Antibody-Related Membranous Nephropathy	5
Efficacy of first-line immune checkpoint inhibitors for recurrent/metastatic head and neck cancer: a systematic review and meta-analysis	5
The potential of CAR T cells in autoimmune diseases	5
Drug evaluation: mepolizumab in chronic obstructive pulmonary disease	5
Overcoming Immune-Resistance in Laryngeal Cancer: A Case Report of the Abscopal Effect and Nivolumab Beyond Progression	5
Plain language summary of disease activity and therapeutic response to pegcetacoplan for geographic atrophy identified by deep learning-based analysis of OCT	5
Imaging-calculated splenic volume is associated with response in melanoma patients treated with immunotherapy	5
Bimekizumab for The Treatment of Psoriasis	5
The Use of Dostarlimab, a Safe and Efficient Monotherapy in Msi-H Rectal Cancer Patients, an Alternative to Surgery	5
A patient empowerment program for primary immunodeficiency improves quality of life in children and adolescents	5
Summary of Certolizumab Pegol in Psoriasis Including Structural Features, Pharmacokinetics and Treatment	5
Impact of low sodium values on survival outcomes of patients with cancer receiving immune checkpoint inhibitors	5
Beyond conventional therapies: immunotherapeutic strategies targeting HPV-associated cervical cancer	5
Late-onset recurrent immune checkpoint inhibitor-related pneumonitis after cessation of pembrolizumab: a case report	5
Friendly fire? A case of inadvertent reactivation and progression of chronic lymphocytic leukemia following the treatment of cutaneous squamous cell carcinoma with Cemiplimab – case report	5
Pharmacokinetics and Safety of CT-P17 (40 mg/0.4 ml) Versus Reference Adalimumab: Randomized Study in Healthy Japanese Adults	5
Cemiplimab-Induced Cytokine-Release Syndrome: Second Case Reported and Review of The Literature	5
Radiation and Resolve: Unlocking the Synergistic Potential of Radioimmunotherapy in Advanced Lung Cancer Management	5
Real-World Study: Drug Reduction in Children With Allergic Rhinitis and Asthma Receiving Immunotherapy	5
Stereotactic body radiation therapy plus adoptive vNKT cell therapy for pancreatic cancer: protocol of a phase II trial	5
Pancreas-specific immune-related adverse events in patients with lung cancer: a case series study	5
Prognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapy	5
Recent advances in bispecific natural killer cell engagers for cancer immunotherapy	5
Effect of Neoadjuvant Therapy on Tumor Tissue PD-L1 and VISTA Expression Levels in Non-Small-Cell Lung Cancer	5
Cost-utility analysis of blinatumomab in pediatric patients with acute lymphoblastic leukemia in Iran	5
Pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction cancer: KEYNOTE-859 Q-TWiST analysis	5
Combination of immunotherapy and fruquintinib in metastatic colorectal cancer: the key to overcome resistance?	5
Immunotherapy for Head and Neck Squamous Cell Carcinoma: Current Status and Perspectives	5
Positioning risankizumab in the treatment algorithm of moderate-to-severe Crohn's disease	5
A Trispecific Antibody Induces Potent Tumor-Directed T-Cell Activation and Antitumor Activity by CD3/CD28 Co-Engagement	5